<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923114</url>
  </required_header>
  <id_info>
    <org_study_id>NL67316.091.18</org_study_id>
    <nct_id>NCT03923114</nct_id>
  </id_info>
  <brief_title>Imaging Pituitary ActiVation by Exendin</brief_title>
  <acronym>iPAVE</acronym>
  <official_title>iPAVE - Imaging Pituitary ActiVation by Exendin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients&#xD;
      with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of type 2 diabetes (T2D) is increasing and a better understanding of the&#xD;
      mechanisms of T2D becomes increasingly important. The glucagon-like peptide 1 receptor&#xD;
      agonists (GLP-1RA), such as exendin, can be used as potent antidiabetic drugs for treatment&#xD;
      of T2D. Not all patients with T2D respond to treatment with GLP-1RA and some even respond&#xD;
      with contradictory effects, but the underlying mechanism for this observation remains&#xD;
      unclear. Interestingly, uptake of an exendin-based radiotracer was observed in the pituitary&#xD;
      gland in diabetes patients. In this study, the effect of GLP-1RA on the HPA axis will be&#xD;
      further studied for an improved understanding of the mechanisms and contradictory treatment&#xD;
      responses.&#xD;
&#xD;
      Patient data will be obtained and will consist of metabolic characterization (laboratory&#xD;
      parameters and oral glucose tolerance test), an ACTH assay and determination of cortisol&#xD;
      excretion. In addition, Ga-68-NODAGA-exendin-4 PET/CT imaging will be performed in 10&#xD;
      patients with treatment response (decrease in HbA1c or weight loss) and 10 patients without&#xD;
      response after GLP-1RA therapy. In 5 patients with high radiotracer uptake, an additional&#xD;
      brain MRI scan will be performed for improved anatomical referencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pituitary uptake of Ga-68-NODAGA-exendin</measure>
    <time_frame>1.5 year</time_frame>
    <description>Comparison of the pituitary uptake (Bq) of Ga-68-NODAGA-exendin-4 obtained by quantitative analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic status (OGTT)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Assessment of the metabolic status by performing an OGTT (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic status (ACTH)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Assessment of the metabolic status by performing an ACTH assay (mol/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patient group with treatment response</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET/CT imaging of patients with response to GLP-1 receptor agonist treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient group without treatment response</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PET/CT imaging of patients with no response to GLP-1 receptor agonist treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Ga-68-NODAGA-exendin-4 PET/CT</intervention_name>
    <description>PET/CT imaging after injection with Ga-68-NODAGA-exendin-4</description>
    <arm_group_label>Patient group with treatment response</arm_group_label>
    <arm_group_label>Patient group without treatment response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with treatment response:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Subject is diagnosed with type 2 diabetes&#xD;
&#xD;
          -  Subject showed response to GLP-1RA treatment&#xD;
&#xD;
          -  Ability to sign informed consent&#xD;
&#xD;
        Patients without treatment response:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Subject is diagnosed with type 2 diabetes&#xD;
&#xD;
          -  Subject showed no response to GLP-1RA treatment&#xD;
&#xD;
          -  Ability to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Pregnancy or the wish to become pregnant within 6 months after the study&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pituitary disorder&#xD;
&#xD;
          -  Inability to sign informed consent&#xD;
&#xD;
          -  Exclusion criteria for MR:&#xD;
&#xD;
               -  Fragments, clips or devices in brain, eyes, spinal canal&#xD;
&#xD;
               -  Implantable defibrillator or pacemaker (wires)&#xD;
&#xD;
               -  Mandibular magnetic implants&#xD;
&#xD;
               -  Neurostimulator, bladder stimulator, non-removable insulin pump&#xD;
&#xD;
               -  Metal tissue-expander in chest&#xD;
&#xD;
               -  Cochlear implant&#xD;
&#xD;
               -  Ossicular replacement prosthesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tom Jansen, MSc</last_name>
    <phone>0031243667244</phone>
    <email>tom.jp.jansen@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marti Boss, MSc</last_name>
    <phone>0031243613813</phone>
    <email>marti.boss@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Jansen, MSc</last_name>
      <phone>0031243667244</phone>
      <email>tom.jp.jansen@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marti Boss, MSc</last_name>
      <phone>0031243613813</phone>
      <email>marti.boss@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exendin</keyword>
  <keyword>GLP-1 receptor agonist</keyword>
  <keyword>HPA-axis</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

